BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22537942)

  • 1. Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.
    Liang H; Zhang J; Shao C; Zhao L; Xu W; Sutherland LC; Wang K
    J Exp Clin Cancer Res; 2012 Apr; 31(1):36. PubMed ID: 22537942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells.
    Su Z; Yin J; Zhao L; Li R; Liang H; Zhang J; Wang K
    World J Surg Oncol; 2014 Dec; 12():367. PubMed ID: 25441176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.
    Deng LL; Deng HB; Lu CL; Guo Y; Wang D; Yan CH; Lv X; Shao YX
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2097-105. PubMed ID: 24994038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulating activated epidermal growth factor receptor has no effect on RBM5 expression.
    Masilamani TJ; Rintala-Maki ND; Wang K; Sutherland LC
    Chin Med J (Engl); 2012 Jul; 125(13):2378-81. PubMed ID: 22882865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of RBM5 induces autophagy in human lung adenocarcinoma cells.
    Su Z; Wang K; Li R; Yin J; Hao Y; Lv X; Li J; Zhao L; Du Y; Li P; Zhang J
    World J Surg Oncol; 2016 Feb; 14():57. PubMed ID: 26923134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.
    Sun L; Zhang Q; Luan H; Zhan Z; Wang C; Sun B
    J Exp Clin Cancer Res; 2011 Mar; 30(1):30. PubMed ID: 21414214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis.
    Oh JJ; Taschereau EO; Koegel AK; Ginther CL; Rotow JK; Isfahani KZ; Slamon DJ
    Lung Cancer; 2010 Dec; 70(3):253-62. PubMed ID: 20338664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumor suppressor gene RBM5 inhibits lung adenocarcinoma cell growth and induces apoptosis.
    Shao C; Zhao L; Wang K; Xu W; Zhang J; Yang B
    World J Surg Oncol; 2012 Aug; 10():160. PubMed ID: 22866867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].
    Han C; Zou H; Ma J; Zhou Y; Zhao J
    Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):882-91. PubMed ID: 20840818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis.
    Oh JJ; Razfar A; Delgado I; Reed RA; Malkina A; Boctor B; Slamon DJ
    Cancer Res; 2006 Apr; 66(7):3419-27. PubMed ID: 16585163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
    Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K
    PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of RBM5-related factors in primary breast tissue.
    Rintala-Maki ND; Goard CA; Langdon CE; Wall VE; Traulsen KE; Morin CD; Bonin M; Sutherland LC
    J Cell Biochem; 2007 Apr; 100(6):1440-58. PubMed ID: 17131366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features.
    Peng J; Valeshabad AK; Li Q; Wang Y
    Oncol Lett; 2013 Mar; 5(3):1000-1004. PubMed ID: 23425895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis.
    Han C; Ma J; Zhao J; Zhou Y; Jing W; Zou H
    Cancer Invest; 2011 Nov; 29(9):626-34. PubMed ID: 22011285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
    Nunez MI; Behrens C; Woods DM; Lin H; Suraokar M; Kadara H; Hofstetter W; Kalhor N; Lee JJ; Franklin W; Stewart DJ; Wistuba II
    J Thorac Oncol; 2012 May; 7(5):833-40. PubMed ID: 22729036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
    Sunaga N; Imai H; Shimizu K; Shames DS; Kakegawa S; Girard L; Sato M; Kaira K; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Int J Cancer; 2012 Apr; 130(8):1733-44. PubMed ID: 21544811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.
    Villalva C; Duranton-Tanneur V; Guilloteau K; Burel-Vandenbos F; Wager M; Doyen J; Levillain PM; Fontaine D; Blons H; Pedeutour F; Karayan-Tapon L
    Cancer Med; 2013 Jun; 2(3):296-304. PubMed ID: 23930206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Ito H; Isaka T; Imai K; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Tsuboi M; Nakayama H; Masuda M
    BMC Cancer; 2014 Aug; 14():610. PubMed ID: 25152277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.